Le Lézard
Classified in: Health
Subjects: NPT, SVY, VET

Cohen Veterans Bioscience Releases Harris Poll Assessing Awareness of PTSD in U.S. Military Veterans


WASHINGTON, April 19, 2018 /PRNewswire-USNewswire/ -- Cohen Veterans Bioscience today announced results of a Harris Poll survey of over 2000 respondents revealing that nearly 9 in 10 Americans (88%) agree that post-traumatic stress disorder (PTSD) is a significant problem among U.S. military veterans. However, only 31 percent of Americans surveyed felt there were enough resources available to help U.S. military veterans with PTSD, with 72 percent of individuals strongly agreeing that the U.S. government should offer additional help to these veterans.

 (PRNewsfoto/Cohen Veterans Bioscience)

PTSD is a clinically diagnosed disorder that can occur following the experience or the witnessing of life-threatening events such as military combat, natural disasters, terrorist incidents, serious accidents, or physical or sexual assault in adulthood or childhood.  Symptoms include flashbacks, nightmares, severe anxiety, uncontrollable intrusive thoughts, and emotional numbing after the event.

Awareness of PTSD as a significant problem was broad, even among individuals not closely affiliated with the U.S. military (89% of respondents who are not veterans or do not have immediate family who are veterans). Americans also see PTSD as a significant problem for veterans, impacting their daily lives including interfering with their ability to hold down a steady job and maintain healthy relationships with family and friends (89%).  The majority (87%) of respondents also recognized that U.S. military veterans typically have other brain health problems such as depression, memory problems, difficulty concentrating, and issues with sleep.

"The results of this survey highlight the gap between the broad public awareness of mental health problems within the U.S. military veteran community experiencing trauma and their perception of the lack of resources available to address this significant issue," commented Cohen Veterans Bioscience Chief Medical Officer Allyson Gage, PhD. "Results such as these embolden us to continue our all-hands approach to tackling this important scientific & clinical challenge to ensure that better treatments for trauma-related brain disorders are developed in years, not decades."

Survey Results Summary

Question wording: How much do you agree or disagree with each of the following statements about post-traumatic stress disorder (PTSD)?

1. PTSD is a significant problem among U.S. military veterans.

n=

2,105

Strongly/Somewhat Agree (NET)

88%

  Strongly agree

66%

  Somewhat agree

22%

Strongly/Somewhat Disagree (NET)

4%

  Somewhat disagree

2%

  Strongly disagree

2%

Not at all sure

7%

 

2. The U.S. government should do more to help U.S. military veterans with PTSD.

n=

2,105

Strongly/Somewhat Agree (NET)

89%

  Strongly agree

72%

  Somewhat agree

16%

Strongly/Somewhat Disagree (NET)

4%

  Somewhat disagree

2%

  Strongly disagree

2%

Not at all sure

7%

 

3. There are enough resources available to help U.S. military veterans with PTSD.

n=

2,105

Strongly/Somewhat Agree (NET)

31%

  Strongly agree

15%

  Somewhat agree

15%

Strongly/Somewhat Disagree (NET)

56%

  Somewhat disagree

29%

  Strongly disagree

27%

Not at all sure

14%

 

4. Military-related PTSD is not the only health problem U.S. military veterans face (i.e., they typically have other brain health problems such as depression, memory problems, difficulty concentrating, sleep issues, etc.).

n=

2,105

Strongly/Somewhat Agree (NET)

87%

  Strongly agree

68%

  Somewhat agree

19%

Strongly/Somewhat Disagree (NET)

4%

  Somewhat disagree

2%

  Strongly disagree

2%

Not at all sure

8%

 

5. Military-related PTSD has major impacts on a person's ability to participate in normal daily activities (e.g., holding down a steady job, maintaining/starting relationships/friendships).

n=

2,105

Strongly/Somewhat Agree (NET)

89%

  Strongly agree

66%

  Somewhat agree

23%

Strongly/Somewhat Disagree (NET)

3%

  Somewhat disagree

1%

  Strongly disagree

2%

Not at all sure

7%

About the Survey

This survey was conducted online in the United States by Harris Poll on behalf of Cohen Veterans Bioscience and Tonix Pharmaceuticals between Jan. 3 to Jan. 5, 2018 among 2,105 U.S. adults ages 18 and older, among whom 983 say they/their immediate family member(s) is a U.S. military veteran. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables, please contact: Victoria Fort (Cohen Bioscience media contact, [email protected], 202.361.0445) or Rich Allan (Tonix media contact, [email protected], 646.942.5588). All references must be sourced Harris Poll/Cohen Veterans Bioscience.

About Cohen Veterans Bioscience

Cohen Veterans Bioscience is a national, nonpartisan research 501(c)(3) organization dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of veterans and civilians who suffer the devastating effects of trauma-related and other brain disorders. To support & learn more about our research efforts, visit www.cohenveteransbioscience.org.

SOURCE Cohen Veterans Bioscience


These press releases may also interest you

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...

at 03:00
An analysis by the World Wildlife Fund (WWF) suggests that the average person ingests as many as 5 grams of microplastics weekly ? that's the equivalent of eating a whole credit card. While the exact effects of plastics on human health are still...



News published on and distributed by: